Compile Data Set for Download or QSAR
Report error Found 2012 Enz. Inhib. hit(s) with Target = 'Glutaminyl-peptide cyclotransferase'
TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687826(US20240246981, Example 54)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687832(US20240246981, Example 60)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687841(US20240246981, Example 69)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687841(US20240246981, Example 69)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50581458(CHEMBL5092802)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of human recombinant glutaminyl cyclase using H-Gln-AMC hydrobromide as substrate measured after 15 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails Article
PubMedPDB3D3D Structure (crystal)
TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50581397(CHEMBL5085353)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human recombinant glutaminyl cyclase using H-Gln-AMC hydrobromide as substrate measured after 15 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50581442(CHEMBL5086776)
Affinity DataIC50: 0.460nMAssay Description:Inhibition of human recombinant glutaminyl cyclase using H-Gln-AMC hydrobromide as substrate measured after 15 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50581399(CHEMBL5085226)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of human recombinant glutaminyl cyclase using H-Gln-AMC hydrobromide as substrate measured after 15 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50581400(CHEMBL5075575)
Affinity DataIC50: 0.600nMAssay Description:Inhibition of human recombinant glutaminyl cyclase using H-Gln-AMC hydrobromide as substrate measured after 15 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50237486(CHEMBL4077433)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of human glutaminyl cyclase assessed as reduction in conversion of H-Gln-AMC hydrobromide to pGlu-AMC preincubated with substrate for 10 m...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50581426(CHEMBL5089771)
Affinity DataIC50: 0.710nMAssay Description:Inhibition of human recombinant glutaminyl cyclase using H-Gln-AMC hydrobromide as substrate measured after 15 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50581398(CHEMBL5083519)
Affinity DataIC50: 0.800nMAssay Description:Inhibition of human recombinant glutaminyl cyclase using H-Gln-AMC hydrobromide as substrate measured after 15 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50581412(CHEMBL5088732)
Affinity DataIC50: 1nMAssay Description:Inhibition of human recombinant glutaminyl cyclase using H-Gln-AMC hydrobromide as substrate measured after 15 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50581450(CHEMBL5085670)
Affinity DataIC50: 1nMAssay Description:Inhibition of human recombinant glutaminyl cyclase using H-Gln-AMC hydrobromide as substrate measured after 15 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652300(US20240059675, Example 4)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652305(US20240059675, Example 8)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652305(US20240059675, Example 8)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652310(US20240059675, Example 13)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652310(US20240059675, Example 13)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652312(US20240059675, Example 15)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652312(US20240059675, Example 15)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652313(US20240059675, Example 16)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652318(US20240059675, Example 21)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652324(US20240059675, Example 26)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652324(US20240059675, Example 26)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652363(US20240059675, Example 32)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652363(US20240059675, Example 32)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687778(US20240246981, Example 6)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687791(US20240246981, Example 19)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687794(US20240246981, Example 22)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687802(US20240246981, Example 30)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM661126(US20240101544, Example 11 | 2-[4-(4-methyl-4H-1,2,...)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687805(US20240246981, Example 33)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687806(US20240246981, Example 34)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687808(US20240246981, Example 36)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687812(US20240246981, Example 40)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687822(US20240246981, Example 50)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687822(US20240246981, Example 50)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687825(US20240246981, Example 53)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687826(US20240246981, Example 54)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687827(US20240246981, Example 55)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687827(US20240246981, Example 55)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687828(US20240246981, Example 56)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687830(US20240246981, Example 58)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687830(US20240246981, Example 58)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687832(US20240246981, Example 60)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687833(US20240246981, Example 61)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687834(US20240246981, Example 62)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687834(US20240246981, Example 62)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687835(US20240246981, Example 63)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 2012 total ) | Next | Last >>
Jump to: